BridgeBio Pharma Inc
(STU:2CL)
€
69.46
-1.54 (-2.17%)
Market Cap: 13.61 Bil
Enterprise Value: 14.97 Bil
PE Ratio: 0
PB Ratio: 0
GF Score: 69/100 BridgeBio Pharma Inc at Piper Jaffray Healthcare Conference Transcript
Dec 03, 2019 / 05:30PM GMT
Tyler Martin Van Buren
Piper Sandler & Co., Research Division - Principal & Senior Biotech Analyst
All right. Great. Thanks again to everyone for coming to Piper Jaffray 31st Annual Healthcare Conference. Welcome. My name is Tyler Van Buren, I'm a biotech analyst here at Piper Jaffray. This next session, we're very pleased to have Neil Kumar, the Founder and CEO of BridgeBio and Eidos here. There's a lot to discuss. So I'll just go ahead and get straight into it.
Neil Kumar
BridgeBio Pharma, Inc. - Co-Founder, CEO & Director
I apologize in advance. I'm losing my voice, a little sick. Hopefully everyone can hear me.
Questions & Answers
Tyler Martin Van Buren;Neil Kumar
Piper Sandler & Co., Research Division - Principal & Senior Biotech Analyst;BridgeBio Pharma, Inc. - Co-Founder, CEO & Director
Yes. And perhaps you could just start by providing a brief overview of the company and the concept behind it and why you decided to go public earlier.
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
7-Day Free Trial · Cancel Anytime
Subscription fee may be tax deductible.
Excellent 

4.6 out of 5
Trustpilot